The staging and management of prostate cancer have been significantly improved by advanced imaging techniques such as magnetic resonance imaging (MRI) and prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT). The gene discussed is FOLH1; the disease is prostate carcinoma.